Merck & Co., Inc. (MRK)

147.69 -0.66 (-0.44%) USD  |  NYSE  |  Aug 31, 14:32
More

Merck Total Long Term Debt (Quarterly) : 51.08B for June 30, 2026

Total Long Term Debt (Quarterly) Chart

View Total Long Term Debt (Quarterly) for MRK.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Long Term Debt (Quarterly) Chart
Start Trial

Historical Total Long Term Debt (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 51.08B
March 31, 2026 46.67B
December 31, 2025 47.65B
September 30, 2025 39.97B
June 30, 2025 33.97B
March 31, 2025 33.48B
December 31, 2024 35.34B
September 30, 2024 34.98B
June 30, 2024 34.72B
March 31, 2024 31.14B
December 31, 2023 34.61B
September 30, 2023 33.97B
June 30, 2023 34.07B
March 31, 2023 28.07B
December 31, 2022 29.76B
September 30, 2022 28.48B
June 30, 2022 28.68B
March 31, 2022 30.59B
December 31, 2021 31.92B
September 30, 2021 22.91B
June 30, 2021 24.03B
March 31, 2021 24.00B
December 31, 2020 26.70B
September 30, 2020 26.32B
June 30, 2020 26.16B
Date Value
March 31, 2020 21.64B
December 31, 2019 23.50B
September 30, 2019 23.46B
June 30, 2019 23.52B
March 31, 2019 23.50B
December 31, 2018 19.81B
September 30, 2018 19.94B
June 30, 2018 19.96B
March 31, 2018 21.50B
December 31, 2017 21.35B
September 30, 2017 21.84B
June 30, 2017 21.71B
March 31, 2017 23.44B
December 31, 2016 24.27B
September 30, 2016 23.66B
June 30, 2016 23.64B
March 31, 2016 23.66B
December 31, 2015 23.93B
September 30, 2015 24.12B
June 30, 2015 24.07B
March 31, 2015 25.51B
December 31, 2014 18.70B
September 30, 2014 18.57B
June 30, 2014 18.59B
March 31, 2014 19.59B

Total Long Term Debt Definition

Represents a company's total debt maturing for more than 12 months of the reporting period.

Read full definition.

Total Long Term Debt (Quarterly) Range, Past 5 Years

View Total Long Term Debt (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Long Term Debt (Quarterly) Benchmarks

View Total Long Term Debt (Quarterly) Benchmarks
Start Trial
Johnson & Johnson 37.34B
Eli Lilly & Co. 49.62B
Pfizer Inc. 63.10B
Bristol Myers Squibb Co. 44.59B
Abbott Laboratories 32.61B